YOU ARE HERE:
Resistance news
page  of 10
 
Headline
Date
  Transmitted drug-resistant HIV stabilising in Europe
21.10.09
  Etravirine, darunavir/ritonavir and raltegravir very effective in highly treatment-experienced patients
19.10.09
  Delays in switching treatment: NRTI resistance can be slower to emerge than expected
08.09.09
  Cheap viral load test is as reliable as standard: Botswana places large order
01.09.09
  Transmission of resistant HIV common in clusters of newly infected individuals
10.06.09
  Starting treatment at lower CD4 cell counts increases risk of HIV drug resistance
02.06.09
  Rate of transmitted drug-resistant HIV stable in France
18.03.09
  Swiss study finds moderate drug resistance; highlights difficulty of interpreting trends in changing treatment populations
16.03.09
  HIV transmission rate in US has declined enormously
16.12.08
  Widespread resistance to antiretrovirals among children in the Central African Republic
03.12.08
  Raltegravir may have role in PEP if exposure involves drug-resistant HIV
20.11.08
  Non-nucleoside resistance is efficiently transmitted within infection ‘clusters’
13.11.08
  South African resistance survey confirms that clade C is more likely to develop multi-drug resistance mutation
12.11.08
  Kivexa downgraded to alternative status in revised US HIV treatment guidelines
05.11.08
  Raltegravir resistance patterns becoming clearer
28.10.08
  Resistance to darunavir related to pre-existing mutations
06.10.08
  Higher levels of drug resistance seen after first-line NNRTI failure than boosted PI failure: meta-analysis
03.10.08
  Cluster of multi-drug resistant HIV transmissions in Seattle
30.09.08
  Widespread NRTI and NNRTI resistance seen in Malawian patients failing first-line antiretroviral therapy
06.08.08
  Low level of drug-resistant strains common in untreated patients, but may not affect treatment
22.07.08

page  of 10